20.500.12556/DiRROS-30472 The prognostic significance of programmed cell death protein 1 and its ligand on lymphoma cells and tumor-immune cells in diffuse large B-cell lymphoma, not otherwise specified Napovedna vrednost izražanja receptorja programirane celične smrti 1 in njegovega liganda na limfomskih celicah in tumorsko-imunskih celicah pri difuznem velikoceličnem B-celičnem limfomu, brez drugih oznak Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) is the most common type non-Hodgkin’s lymphoma, where the treatment of relapsed/refractory cases is the major challenge. Programmed cell death protein 1 (PD-1) and its ligand PD-L1 play a crucial role in the negative regulation of the immune response against the disease. The aim of the study was to analyze the expression of PD-1 and PD-L1 on lymphoma cells (LCs) and tumor-immune cells (TICs) and to investigate their correlation with outcome. Samples from 283 patients diagnosed with DLBCL, NOS (both germinal center B cell like [GCB] and non-GCB subtypes) were included in the study. Expression of PD-1 and PD-L1 was determined using double immunohistochemical staining (D-IHC) for PD-1/PAX5 and PD-L1/PAX5 on tissue microarrays. LCs were highlighted by D-IHC to obtain more accurate results. Clinical data and histologic diagnoses were obtained from electronic data records. We correlated clinical characteristics, and PD-1 and PD-L1 expression on LCs and TICs with progression-free survival (PFS) and overall survival (OS). Expression of PD-1 on TICs was observed in 38.4% and on LCs in 8.8% of cases, while PD-L1 was expressed on TICs in 46.8% and on LCs in 6.5% of cases. PD-L1 expression on LCs was more frequent in non-GCB subtype (p = 0.047). In addition, patients with PD-L1 expression on LCs had significantly shorter PFS (p = 0.015), and the expression retained significant in the multivariate model (p = 0.034). PD-L1 was more frequently expressed in LCs of the non-GCB subtype. Additionally, PD-L1 in LCs may predict shorter PFS time. D-IHC staining for PD-L1/PAX5 is a feasible method to assess PD-L1 expression on LCs of DLBCL, NOS patients and can be used to identify patients who may benefit from targeted immunotherapy with checkpoint inhibitors. diffuse large b-cell lymphoma immunohistochemistry cytopathology difuzni velikocelični limfom B imunohistokemija citopatologija true false true Association of Radiology and Oncology Ljubljana Angleški jezik Slovenski jezik Neznano 2026-06-26 14:10:09 2026-06-26 14:10:10 2026-06-27 03:52:15 0000-00-00 00:00:00 2024 0 0 str. 99-109, X no. 1 Vol. 58 Mar. 2024 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2024-03-01 616-07 1318-2099 10.2478/raon-2024-0010 189584899 RAZ_Cas_Slak_Teja_2024.pdf RAZ_Cas_Slak_Teja_2024.pdf 1 A8AD1398F2E438E7046399F441E858F0 eb411034adfb31c04c049541201bdee190462cf23dce4900368fa31cd3d1ca71 167bd30b-7158-11f1-b414-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=46278 Društvo radiologije in onkologije Onkološki inštitut Ljubljana 0 0 0